Duringthecellcycleofmostsomaticcells,DNAsynthesis(S-phase)andmitosis(M-phase)areseparatedbytwogapphases(G1andG2)ofvaryingduration.Regulationofcellcycleprogressionineukaryoticcellsdependsontheexpressionofcyclinproteins.Membersofthecyclinfamilyofproteinscombinewithacyclindependentkinases(CDKs)subunittoformtheactivekinase,whichinitiatesG2toMandG1toStransition.ThelatterarecontrolledbycyclinstermedG1cyclins,whichcommitthecelltoDNAreplication.AtleastfivecandidateG1-phasecyclins,termedcyclinsC,D1,D2,D3,andEhavebeenidentifiedinmammaliancells.D-typecyclinsareinducedduringtheG1phaseofthemammaliancellcycleinresponsetoavarietyofmitogenicgrowthfactors.Onceinduced,theD-typecyclinsaccumulateincomplexeswithCDKs,whosekinaseactivityisthoughttobenecessaryfordrivingcellsintoSphase.ThemajorcatalyticpartnersoftheD-typecyclinsareCDK4andCDK6,butatleastsomeD-typecyclinsalsointeractwithotherCDKs,includingCDK2andCDK5.CyclinD1-andD2-associatedCDK4and/orCDK6kinaseactivitieshavebeendetectedinmid-G1,priortotheactivationofanyotherknownCDK,andtheyculminateinlateG1phase.AmplificationofthecyclinD1genehasbeenobservedinasignificantpercentageofcancers,includingbreast,squamous,andesophagealcarcinomas.
Imageshowsimmunohistochemicalstainingofparaffin‐embeddedhumanbreastadenocarcinomaxenografttumorsectionstainedwithCyclinD1antibodyusingtheEtonBio"sCyclinD1IHCKit.CyclinD1(darkbrown)displaysanuclearlocalizationpatternwhichcorrelatesitsfunctioninregulatingcycleprogression(20X,counterstainedwithhematoxylin).
Reagentsprovidedinthekit
TheCyclinD1ImmunohistostainingKithasbeendesignedforthestainingoftissuesthathavebeenfixed(usuallyinneutralbufferedformalin)andsubsequentlyembeddedinparaffinbeforesectioning.Thisprotocolisrecommendedasastartingpoint.Wheneverusinganewantibodyorimmunohistochemistrykit,optimizationbytheindividualend-usermayberequired.
Note:
•Donotallowspecimenstodryduringthestainingprocedure.Specimendryingmaycauseincreasednon-specificstainingandbackground.
•Sometissuemayneedtobaketoremoveover-coveredparaffinpriortotheprocedure.Ifneeded,bakeat55-60°Cfor30minutes.
I.Deparaffinizationandrehydration
Priortostaining,tissuesectionsmustbedeparaffinizedandrehydrated.Incompleteremovalofparaffincancausepoorstainingofthesection.
II.Heatinducedantigenretrieval(HIAR)
Mostformalin-fixedtissuerequiresanantigenretrievalstepbeforeimmunohistochemicalstainingcanproceed.Heatinducedantigenretrievalcanbeperformedusingasteamer,pressurecooker,oramicrowave.Theretrievaltimewritteninthisprotocolisbasedonusingaretrievalsteamer.Theheatingtimemayneedtobeadjustedifyouuseadifferentdeviceandmethod.
1.Fillplasticcoplinjar/containerwithAntigenRetrievalBuffer(0.01MCitrateBuffer,pH6.0,notincludedinthekits).
PrepareStockSolution:
0.1MSodiumCitrate--20.5mL
0.1MCitricAcid--4.5mL
Adddistilledwaterto250mL
2.Placethecoplinjar/containerinsteamerwithlid.
3.Turnonsteamerandpreheatto90‐100°C.Carefullyputslidesintothecoplinjar/containerandsteamfor40min(95‐100°C).
4.Turnoffthesteamer,removethecoplinjar,placeatroomtemperatureandallowslidestocoolfor20min.Keepthejarcoveredallthetime.
5.Rinseslidebyincubationofslideindistilledwaterfor3minutes.Repeatthissteptwiceandbeginstainingprocedure.
III.Stainingprocedure
PeroxidaseBlockingisoptional.Ifnonon-specificstainingisobserved,skipthesestepsandgotostep3.
BlockingofEndogenousPeroxidase
Note:PeroxidaseBlockingisoptional.Ifnonon-specificstainingisobserved,skipthesestepsandgotostep3.
BlockingofNon-specificbinding
Note:10Xblockingbuffermayformprecipitatesat4°C.Completelydissolvetheprecipitatesbeforemakingworkingsolution
PrimaryAntibody
Secondary/HRPConjugates
DABChromogen
13.TapoffexcessPBS.ApplyenoughDABSubstrateSolutiontocoverspecimenimmediatly.Checkdarkbrowncolordevelopmentundermicroscopeandincubateuntildesiredstainintensitydevelops.
DistilledWater--860μL
10XDABsubstratebuffer--100μL
0.3%HydrogenPeroxidesolution--15μL
DABChromogen--25μL
Counterstaining
Mounting
IV.InstructionforHematoxylincounterstaining
Problems | PossIBLeCauses | Solutions |
Overstaining | 1.Toolongincubationtimeofprimaryantibody,ortoohightemperaturewhendoingstaining 2.ToolongincubationtimeofDABsubstrate. 3.Slidedriedduringstainingprocess | •Dependingontissuesections,theincubationtimeofprimaryantibodycanbereducedto2hours;Checktheroomtemperaturerangeisat20-250Cwhendoingstaining. •ReduceincubationtimeofDABsubstrate •Avoidsectionstodryduringstainingprocess. |
Weakornostaining | 1.Incompleteremovalofparaffin 2.Tissuesover‐fixation 3.Notefficientantigenretrieval 4.Reagentsnotusedinproperorderoromittedsteps 5.Expiredantibodyorreagents | •Deparaffinizesectionslongerorchangetofreshxylene;sometissuearraymayneedtobaketo removeover‐coveredparaffin. •Increasingtheconcentrationofprimaryantibodyto1:40;ifthisdoesnotwork,reducedurationof post‐fixation. •Adjustantigenretrievaltimebasedonthesettingforsectionfixationandretrievaldeviceused. •Reviewnotesandprocedureused. •Checkkitexpirationdatesandkitstorageconditions |
Highbackground | 1Sectionsdriedduringstainingprocess 2Slidenotrinsedthoroughly 3Antigenover‐retrieval | •Donotallowsectionstodryduringstainingprocess;usehumidcontainerduringincubation withprimaryantibody. •Usefreshsolutioninbufferjars;rinseatleastthreetimesbetweensteps. •Optimizeantigenretrievaltimeifyouusedmicrowaveorpressurecookerforretrieval. |
Everest Biotech公司成立于2000年,由英国牛津大学一批生物化学家创建。公司科学家团队具有丰富的抗体纯化及蛋白组学专业知识,雄厚的专业背景赋予了公司能为全球科研人员提供高质量、创新性抗体产品的能力。目前,Everest Biotech可提供3000余种抗体,涉及肿瘤、自身免疫、过敏、心血管疾病、传染病、代谢、神经科学等领域。所有抗体均由Everest Biotech自主研发生产、全部经过肽亲和纯化以保证最佳的特异性和纯度、经过免疫原肽的ELISA和WB实验验证; 由PhD科学家团队提供全方位技术支持服务。Everest Biotech为众多国际知名抗体公司提供OEM服务。